What is the recommended evaluation and management for a patient with hyperinsulinemia?

Evaluation and Management of Hyperinsulinemia

For adults with suspected hyperinsulinemia, document hypoglycemia with simultaneous measurement of plasma glucose, insulin, C-peptide, proinsulin, β-hydroxybutyrate, and screen for oral hypoglycemic agents during a spontaneous episode or provoked by a 72-hour fast; if endogenous hyperinsulinism is confirmed (insulin ≥3.0 µU/ml, C-peptide ≥0.6 ng/ml with glucose <55 mg/dL), proceed with imaging to localize an insulinoma. 1

Diagnostic Approach

Initial Evaluation - Critical Laboratory Criteria

When evaluating a seemingly well individual with suspected hyperinsulinemia, the diagnostic strategy differs fundamentally based on age:

For Adults:

• Capture biochemical evidence during hypoglycemia (glucose <55 mg/dL) with simultaneous measurements of:

  • Insulin ≥3.0 µU/ml (18 pmol/L)
  • C-peptide ≥0.6 ng/ml (0.2 nmol/L)
  • Proinsulin ≥5.0 pmol/L
  • β-hydroxybutyrate ≤2.7 mmol/L
  • Screen for oral hypoglycemic agents
  • Measure insulin antibodies 1

• If spontaneous episodes cannot be observed, perform a supervised 72-hour fast or post-mixed-meal testing to recreate the hypoglycemic circumstances 1

• A plasma glucose rise ≥25 mg/dL after 1.0 mg IV glucagon confirms insulin-mediated hypoglycemia 1

For Infants and Children: The presentation and etiology differ substantially. Congenital hyperinsulinism results from mutations in 12 key genes (ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, UCP2, HNF4A, HNF1A, HK1, PGM1, PMM2) affecting β-cell insulin regulation 2. The critical danger is suppressed ketone formation despite hypoglycemia, dramatically increasing brain injury risk 2.

Differential Diagnosis - Key Distinctions

The most common causes vary by population:

Adults: Insulinoma (incidence 1 in 250,000 patient-years) presents with neuroglycopenia primarily during fasting, though occasionally postprandial 1. Consider surreptitious insulin/sulfonylurea use, particularly in those with healthcare access 1. Post-gastric-bypass hyperinsulinism from nesidioblastosis typically occurs months post-surgery with postprandial symptoms 1.

Neonates/Infants: Perinatal stress-induced transient hyperinsulinism is most common. Persistent forms include focal lesions (surgically curable) versus diffuse disease 3, 4.

Emerging Recognition: INSR gene variants cause a paradoxical phenotype combining postprandial hypoglycemia with ketonemia, insulin resistance, normal BMI, and normal triglycerides—distinct from typical insulinoma patterns 5.

Localization for Surgical Candidates

Once endogenous hyperinsulinism is biochemically confirmed with negative oral hypoglycemic screening and absent insulin antibodies, proceed systematically:

1. CT or MRI of pancreas
2. Transabdominal and endoscopic ultrasonography
3. Selective pancreatic arterial calcium stimulation with hepatic venous insulin sampling if non-invasive imaging is negative 1

For children, 18F-DOPA PET/CT scanning has revolutionized focal lesion identification, though availability remains limited to specialized centers 4, 2.

Management Strategies

Medical Management - Infants and Children

Diazoxide is the first-line pharmacotherapy for congenital hyperinsulinism responsive to medical treatment. 3

Dosing Protocol:

• Dose range: 5-15 mg/kg/day divided into 2-3 doses 3
• Starting dose selection: Use lower doses (toward 5 mg/kg/day) for suspected perinatal stress-induced HI or underlying cardiac disease; higher doses for genetic forms 3
• Maximum dose: Do not exceed 15 mg/kg/day 3
• Titration: Adjust to clinical effect based on glucose stability >70 mg/dL 3

Critical Safety Measures:

• Mandatory thiazide co-administration: Start chlorothiazide 10-20 mg/kg/day (divided 1-2 times daily) or hydrochlorothiazide 1-2 mg/kg/day (divided twice daily) simultaneously with diazoxide to prevent fluid retention and pulmonary hypertension 3
• Cardiac assessment: Perform thorough cardiac examination and consider baseline echocardiogram before initiating diazoxide 3
• Cardiology consultation required for infants with pulmonary hypoplasia, cardiomyopathy, or significant structural heart disease 3
• Endocrinology consultation mandatory before prescribing diazoxide in infants 3

Special Consideration for Perinatal Stress-Induced HI: Strongly consider delaying diazoxide until after 7-10 days of life if euglycemia can be maintained by other means (IV dextrose, frequent feeds), especially in premature infants, small for gestational age, infants of diabetic mothers, or those with respiratory distress/bronchopulmonary dysplasia 3. This avoids unnecessary medication exposure when spontaneous resolution is likely.

Weaning Protocol for Transient Forms: If transient hyperinsulinism is suspected, reduce diazoxide dose every 2-4 weeks when glucose remains stable >70 mg/dL. After discontinuation, monitor glucose closely for at least 5 days and perform a 15-18 hour safety fast to confirm resolution 3.

Surgical Management

For focal lesions: Surgical resection is curative. In children, laparoscopic or open pancreatectomy guided by preoperative localization achieves excellent outcomes 2. Recurrence rate is 7% in non-MEN-1 patients versus 21% with MEN-1 1.

For diffuse disease unresponsive to medical therapy: Near-total pancreatectomy may be necessary, though this creates lifelong diabetes risk 2.

Post-gastric-bypass hyperinsulinism: Partial pancreatectomy guided by selective arterial calcium stimulation results can ameliorate symptoms in nesidioblastosis 1.

Adult Insulinoma Management

Surgical resection remains the definitive treatment. Long-term survival is excellent after successful removal 1. For inoperable cases, diazoxide or somatostatin analogs may provide symptomatic control.

Critical Pitfalls to Avoid

1. Missing the diagnosis in neonates: Any infant requiring glucose infusion rates >10-13 mg/kg/min to maintain euglycemia should trigger immediate hyperinsulinism evaluation 6. Delayed recognition causes irreversible brain injury 2.

2. Starting diazoxide without thiazide: This combination error significantly increases pulmonary hypertension risk, a potentially fatal complication 3.

3. Overlooking factitious hypoglycemia: Always screen for exogenous insulin and oral hypoglycemic agents before pursuing invasive localization procedures 1. Consider insulin antibody testing to distinguish autoimmune causes 7.

4. Premature diazoxide in perinatal stress cases: Waiting 7-10 days when possible avoids unnecessary medication exposure in self-resolving cases 3.

5. Failing to recognize INSR variants: The paradoxical combination of postprandial hypoglycemia with ketonemia, insulin resistance, and normal weight should prompt INSR genetic testing rather than pursuing insulinoma workup 5.

6. Inadequate biochemical documentation: Attempting localization without proper biochemical confirmation of endogenous hyperinsulinism leads to unnecessary procedures and missed alternative diagnoses 1.